TGFB1 and neoplasm: The research team led by Carl H. June previously demonstrated that overexpressing a dominant-negative mutant of the TGFβR II gene in PSMA-targeting CAR-T cells significantly inhibited TGF-β signaling within the tumor, thereby greatly enhancing the antitumor efficacy of CAR-T cells [70].